Company news
Almirall Sa (BME:ALM) news
Every Almirall Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology
August 10, 2026
Alantra Partners S A : Private Equity invests in Deudafix to build Southern Europe’s leading financial solutions platform for individuals
August 4, 2026
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Mont...
July 20, 2026
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Bus...
May 11, 2026
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
May 4, 2026
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
April 13, 2026
Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology
March 30, 2026
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
March 27, 2026
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
March 26, 2026
Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and...
March 23, 2026
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis
March 16, 2026
Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships
March 12, 2026
etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall
February 24, 2026
Almirall’s 2025 Results
February 23, 2026
EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall
February 9, 2026
Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne
January 29, 2026
Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 15, 2026
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Con...
January 14, 2026
Almirall’s 2025 9M Results
November 10, 2025
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
October 23, 2025
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treat...
September 18, 2025
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
September 17, 2025
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
August 12, 2025
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
August 7, 2025
Almirall H1 2025 Results, Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Drive...
July 28, 2025
Almirall H1 2025 Results
July 25, 2025
Almirall Q1 2025 Results
May 12, 2025
Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology
March 21, 2025
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satis...
March 7, 2025
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025
March 6, 2025
Almirall surpassed guidance for 2024, entering an era of sustained growth and further advancing its Medical Dermatology pipeline
February 25, 2025
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Med...
February 24, 2025
Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare
December 4, 2024